Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18.66 % -4.3%
Debt-to-equity 0.11 % -12.5%
Return On Equity -0.43 % +6.1%
Return On Assets -0.39 % +4.8%
Operating Margin -39.14 % -3.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 173,322,385 shares +3.5%
Common Stock, Shares, Outstanding 172,631,268 shares +3.4%
Entity Public Float 859,300,000 USD -42.7%
Common Stock, Value, Issued 168,000 USD +0.6%
Weighted Average Number of Shares Outstanding, Basic 172,389,209 shares +22.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 8,356,000 USD -16.5%
Revenue from Contract with Customer, Excluding Assessed Tax 8,356,000 USD -16.5%
General and Administrative Expense 61,399,000 USD -19.7%
Operating Income (Loss) -327,086,000 USD +13.9%
Net Income (Loss) Attributable to Parent -297,593,000 USD +13.8%
Earnings Per Share, Basic -1 USD/shares +33.8%
Earnings Per Share, Diluted -1 USD/shares +33.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 91,564,000 USD -39.9%
Accounts Receivable, after Allowance for Credit Loss, Current 211,000 USD -12.4%
Other Assets, Current 3,744,000 USD -44.9%
Assets, Current 624,014,000 USD -27.9%
Property, Plant and Equipment, Net 2,359,000 USD -67.3%
Operating Lease, Right-of-Use Asset 41,369,000 USD -22.5%
Assets 670,000,000 USD -28%
Accounts Payable, Current 2,752,000 USD -59.9%
Accrued Liabilities, Current 25,132,000 USD -24.3%
Liabilities, Current 32,605,000 USD -30.6%
Operating Lease, Liability, Noncurrent 29,686,000 USD -33%
Liabilities 62,291,000 USD -31.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 493,000 USD -80.4%
Retained Earnings (Accumulated Deficit) -1,959,879,000 USD -17.9%
Stockholders' Equity Attributable to Parent 607,709,000 USD -27.6%
Liabilities and Equity 670,000,000 USD -28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73,210,000 USD -45.5%
Net Cash Provided by (Used in) Financing Activities 48,922,000 USD +36.7%
Net Cash Provided by (Used in) Investing Activities 42,465,000 USD +3%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 172,631,268 shares +3.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30,745,000 USD -4.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 93,822,000 USD -39.3%
Deferred Tax Assets, Valuation Allowance 431,929,000 USD +44.1%
Deferred Tax Assets, Gross 445,808,000 USD +42.8%
Depreciation 1,208,000 USD -13.4%
Payments to Acquire Property, Plant, and Equipment 384,000 USD -78.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -299,609,000 USD +11.7%
Property, Plant and Equipment, Gross 34,823,000 USD +0.99%
Operating Lease, Liability, Current 3,643,000 USD -34.1%
Deferred Tax Assets, Operating Loss Carryforwards 166,311,000 USD +17.6%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 2,566,927,000 USD +2.7%
Deferred Tax Assets, Net of Valuation Allowance 13,879,000 USD +13.2%
Share-based Payment Arrangement, Expense 94,139,000 USD +9.4%